Joseph McGuirk

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Joseph McGuirk
May 2, 2025, 09:06 | Blog
Jonathan Friedberg: Comparison of Ide-cel Versus Cilta-cel in Relapsed/Refractory Multiple Myeloma
Jonathan Friedberg, Director at Wilmot Cancer Institute, posted on X: "The results of this analysis…
Mar 4, 2025, 04:35 | Blog
Razan Mohty: Outcomes of anti-CD19 CART for lymphoma in octogenarians
Razan Mohty, Assistant Professor at UAB Medicine, shared a paper she and her colleagues authored…
Jan 23, 2025, 02:32 | Blog
Muhammad Umair Mushtaq: Successful Use of a Midline Catheter for Leukapheresis in Immune Effector Cell Therapy
Muhammad Umair Mushtaq, Associate Professor of Medicine at the University of Kansas Medical Center, shared…
Dec 17, 2024, 01:10 | Science
Hung Trinh: Optimizing the post-CAR T monitoring period in recipients of Axi-cel, Tisa-cel, and Liso-cel by Nausheen Ahmed et al.
A recent paper by Nausheen Ahmed, Medical Director of BMT Survivorship Program at The University…
Aug 12, 2024, 02:23 | Blog
Rafael Fonseca: Defining CRS and ICANs risks
Rafael Fonseca shared a post by USMIRC News, on X: "Clearly defines risk of CRS and…
Aug 5, 2024, 00:11 | Insight
5 year outcomes of SOC Axicabtagene Ciloleucel
Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre,…
Aug 4, 2024, 09:41 | Insight
Michael Jain: 5-year outcomes of standard-of-care Axicabtagene Ciloleucel in lymphoma patients
Michael Jain, Oncologist at Moffitt Cancer Center, shared on X: "What is important for long-term…
Jul 30, 2024, 07:06 | Insight
Aaron Goodman: An informative paper about CD19 CART timing of complications
Aaron Goodman shared on X about a recent paper by Nausheen Ahmed et al. titled…
All: 8 Posts: 1 - 100
Special Coverage